Table 2.
Correlations between characteristics and sarcopenia in patients undergoing radical esophagectomy
| Variable | Total cases | TPI reduction rate mild group | TPI reduction rate severe group | P value |
|---|---|---|---|---|
| Total cases, n (%) | 72 (100) | 36 (50%) | 36 (50%) | - |
| Age at RE (y), median (IQR) | 66 (43 - 83) | 66 (55 - 83) | 66 (44 - 82) | 0.9380a |
| ASA, n (%) | 0.6908b | |||
| 1, 2 | 65 (90%) | 33 (92%) | 32 (89%) | |
| ≥ 3 | 7 (10%) | 3 (8%) | 4 (11%) | |
| Preoperative sarcopeniad, n (%) | 0.4533b | |||
| Sarcopenic | 64 (89%) | 33 (92%) | 31 (86%) | |
| Nonsarcopenic | 8 (11%) | 3 (8%) | 5 (14%) | |
| Tumor location, n (%) | 0.5798c | |||
| Ce/Ut | 17 (24%) | 10 (28%) | 7 (19%) | |
| Mt/Lt/Ae | 55 (76%) | 26 (72%) | 29 (81%) | |
| pStage, n (%) | 0.3450b | |||
| < pStage III | 36 (50%) | 21 (58%) | 15 (42%) | |
| ≥ pStage III | 36 (50%) | 15 (42%) | 21 (58%) | |
| Preoperative therapy, n (%) | 0.5675c | |||
| None | 17 (24%) | 8 (22%) | 9 (25%) | |
| Chemotherapy | 54 (75%) | 28 (78%) | 26 (72%) | |
| Chemoradiotherapy | 1 (1%) | 0 (0%) | 1 (3%) | |
| Postoperative therapy, n (%) | 0.5675c | |||
| None | 17 (24%) | 8 (22%) | 9 (25%) | |
| Chemotherapy | 51 (75%) | 28 (78%) | 26 (72%) | |
| Chemoradiotherapy | 1 (1%) | 0 (0%) | 1 (3%) | |
| Operative procedure, n (%) | 0.0407b | |||
| Open esophagectomy | 22 (31%) | 7 (19%) | 15 (42%) | |
| Thoracoscopic esophagectomy | 50 (69%) | 29 (81%) | 21 (58%) | |
| Blood loss (ml), median (IQR) | 330 (150 - 510) | 230 (110 - 405) | 370 (255 - 723.75) | 0.0087a |
| Operative time (min), median (IQR) | 616.5 (553.5 - 698) | 622 (540.75 - 728.5) | 610.5 (559.25 - 676.5) | 0.4885a |
TPI total psoas major muscle mass index, RE radical esophagectomy, IQR interquartile range, ASA the American Society of Anesthesia physical status, pStage pathological stage (UICC 8th), aWilcoxon rank-sum test, bFisher’s exact test, cChi-square test, dAccording to the definition of Prado [22]